Syn-Ake
A synthetic tripeptide that mimics the activity of Waglerin-1 from Temple Viper venom, blocking nicotinic acetylcholine receptors to produce muscle-relaxing, anti-wrinkle effects.
⚠ Research & Educational Use Only. Syn-Ake is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Blocks postsynaptic nicotinic acetylcholine receptors at neuromuscular junctions - complementary mechanism to Argireline
- Reduces muscle contraction frequency at facial expression muscles, softening dynamic lines
- Clinical study showed 52% reduction in wrinkle depth after 28 days at 4% concentration
- Syn-Ake is not FDA-approved for human use. Cosmetic ingredient. Approved for topical use globally.
Research At a Glance
- Blocks postsynaptic nicotinic acetylcholine receptors at neuromuscular junctions - complementary mechanism to Argireline
- Reduces muscle contraction frequency at facial expression muscles, softening dynamic lines
- Clinical study showed 52% reduction in wrinkle depth after 28 days at 4% concentration
- Enhances skin smoothness and reduces roughness measurably in clinical assessments
What is Syn-Ake?
Syn-Ake is a synthetic tripeptide (dipeptide diaminobutyroyl benzylamide diacetate) developed by Pentapharm (Switzerland) that mimics the activity of Waglerin-1, a peptide component from the venom of the Temple Pit Viper (Tropidolaemus wagleri). Unlike genuine snake venom, Syn-Ake is a precisely engineered synthetic molecule that reproduces only the specific muscle-relaxing mechanism of Waglerin-1, without any toxic components.
The mechanism of Syn-Ake differs importantly from Argireline. While Argireline acts pre-synaptically (inhibiting acetylcholine release from the nerve terminal), Syn-Ake acts post-synaptically - it blocks the muscular nicotinic acetylcholine receptor (mAChR) on the muscle fibre surface. By blocking the receptor, it prevents acetylcholine from binding and triggering muscle contraction, even if acetylcholine has been released normally. This postsynaptic blockade complements the presynaptic inhibition by Argireline, making the two peptides logical partners in anti-expression-line formulations.
The clinical evidence for Syn-Ake is notably strong for a cosmetic peptide. A double-blind, placebo-controlled study at 4% concentration demonstrated a 52% reduction in wrinkle depth after 28 days of twice-daily application - an effect size that competes with prescription retinoids for expression lines. Skin roughness, texture, and smoothness measurements all showed statistically significant improvement in the treatment group.
The "snake venom facial" trend in aesthetic medicine - featuring treatments with snake venom toxins delivered topically - popularised the concept that venom-derived peptides could relax facial muscles without injection. Syn-Ake represents the scientifically rigorous, standardised pharmaceutical approach to this concept: a single synthetic molecule with a defined target, predictable action, and excellent safety profile.
Formulations combining Syn-Ake with Argireline and matrix peptides like Matrixyl represent a comprehensive multi-target approach to reducing expression lines: Argireline reduces acetylcholine release, Syn-Ake blocks postsynaptic receptors, and Matrixyl rebuilds the collagen scaffold that gives skin its structural support.
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Syn-Ake. See all Skin & Anti-Aging peptides for comparison.
Common Stacks
Syn-Ake is frequently combined with the following peptides for synergistic effects. Click any peptide to compare profiles before deciding.
CJC-1295 provides systemic GH axis activation while AOD-9604 specifically targets fat metabolism - a complementary fat loss and body composition stack.
Ipamorelin adds GH pulse stimulation to AOD-9604's direct lipolytic effects for a comprehensive metabolic protocol.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports.
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Syn-Ake is used as a topical cosmetic ingredient at 2-4% concentration. Apply once or twice daily to target expression areas.
Typical concentration: 2-4% Application: once to twice daily, to forehead, crow's feet, perioral area Onset: visible improvement typically within 4 weeks Often combined with Argireline for dual neuromuscular pathway targeting
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Apply topical formulation to cleansed, dry skin. Concentrate on dynamic expression lines. Gently pat into skin until absorbed. Follow with moisturiser. For maximum benefit, use consistently morning and evening.
Explore Further
Quick Reference
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.